The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Advancements in prognostic biomarkers for personalized therapy in multiple myeloma
Siobhan Glavey, MD, PhD, Royal College of Surgeons in Ireland, Dublin, Ireland, explains that molecular technologies have enabled the investigation of several prognostic biomarkers for multiple myeloma. Subsequently, this has aided in predicting survival outcomes and treatment response in patients with multiple myeloma. Prof. Glavey further discusses how the integration of these biomarkers into routine diagnostic strategies for multiple myeloma is needed to allow patients to receive more personalized therapies in the future. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
